Ligand Pharmaceuticals (LGND) to acquire Xoma Royalty (XOMA) for c. USD 740mln, WSJ reports citing sources

Ligand Pharmaceuticals' acquisition of Xoma Royalty for approximately USD 740 million signals a strategic expansion into royalties that could enhance their revenue stream. This move may be viewed positively by investors if it is seen as financially prudent and strategically aligned, potentially boosting Ligand's position in the market while also reflecting confidence in future growth prospects.